Working off of this effect, sodium cellulose phosphate will bind with divalent intestinal cations.
Typical symptoms of this condition include renal stones, bone pain, abdominal discomfort, and nausea/vomiting.
The major US dosage form of sodium cellulose phosphate is Calcibind, which was developed and brought to market by Mission Pharma.
Calcibind is a powder dosage form, which comes in small, 2.5 gram doses, individually packaged.
In the late 1970s and early 1980s, physiological action studies took place to show how intestinal calcium was absorbed and how it affects other functions within the body.